Paradigm Biopharmaceuticals granted European patent
During 2018, Paradigm will release the results of its two phase II arthritis clinical trials.
Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 8 of 9
Paradigm Biopharmaceuticals ahead of schedule with trials
The company is well advanced with two clinical trials aimed at diseases for which there are very few safe and effective drugs.
Paradigm Biopharmaceuticals meets primary endpoint in clinical trial
Paradigm aims to repurpose pentosan polysulfate sodium (PPS), an FDA-approved drug.
Paradigm Biopharmaceuticals funded into 2019 through placement
The placement was expanded due to strong demand from investors.
Paradigm Biopharmaceuticals to finalise raising
The halt will remain in place until Monday 6th November 2017.
Paradigm has successfully dosed first participant in clinical trial for osteoarthritis
The commencement of participant dosing follows ethics approval.
Paradigm reveals outcomes from patient case studies on Osteoarthritis
The Osteoarthritis market represents a significant opportunity for Paradigm.
Paradigm Biopharmaceuticals receives ethics approval for trial on knee osteoarthritis
Knee osteoarthritis is a condition with a significant unmet medical need.
Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial
The clinical trial is of the drug Pentosan Polysulfate Sodium for the treatment of Ross River virus.
Paradigm Biopharmaceuticals shares continue uptrend on leverage to Pentosan Polysulfate Sodium
PPS is a new multi-acting treatment for hay fever, bone bruising and viral arthritis.
Paradigm Biopharmaceuticals shares jump 75% in morning trade
PPS is a new multi-acting treatment for hay fever, bone bruising and viral arthritis
Paradigm Biopharmaceuticals doses first Ross River participant
The Ross River virus affects hundreds of thousands of people in South Asia each year and there is currently no effective treatment for either disease
Paradigm Biopharmaceuticals Ltd to commence Ross River trial
This will be the company's fourth active clinical trial.
Paradigm Biopharmaceuticals CEO lifts stake over 22%
Paradigm will focus on the Phase 2 Bone Marrow Edema clinical trial.
Paradigm Biopharmaceuticals CEO buys shares on-market
Paul Rennie is a major shareholder in the company.
Paradigm Biopharmaceuticals enters US$18 billion global heart failure market
Paradigm has signed a worldwide exclusive in-license agreement.
Paradigm Biopharmaceuticals receives hay fever update
The company remains on track for its other PPS-related programs.
Paradigm Biopharmaceuticals in a trading halt as news pending
The halt will remain in place until Monday 19th June 2017.
Paradigm Biopharmaceuticals gets approval for Ross River trial
The ethics approval means this is Paradigm's fourth active clinical trial.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
Paul Rennie talked timeline to clinical trial results with investors.